- Home
- NEOV vs FENC Comparison
NEOV vs FENC Comparison
Compare NEOV & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.73
HOLD
Current Price
$7.44
Company Overview
Basic Information| Metric | NEOV | FENC |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.6M | 266.4M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | NEOV | FENC |
|---|---|---|
| Price | $3.73 | $7.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 481.4K | 120.6K |
| Earning Date | 05-08-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 96.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $47,538,000.00 |
| Revenue This Year | $150.56 | N/A |
| Revenue Next Year | $5.31 | $70.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.69 |
| 52 Week Low | $1.81 | $4.68 |
| 52 Week High | $7.13 | $9.92 |
Technical Indicators
Market Signals| Indicator | NEOV | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 41.25 |
| Support Level | $3.49 | $7.44 |
| Resistance Level | $3.80 | $8.19 |
| Average True Range (ATR) | 0.29 | 0.43 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 61.68 | 11.79 |
Price Performance
Historical Comparison NEOV
FENC
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.